Table 1.
Clinical profiles of T2DM patients treated with oral hypoglycemic agents (OHAs) in study 1
| SU | BG | α-GI | TZD | Glinide | DPP-4 inhibitor | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N = 629 | N = 1305 | P-value | N = 592 | P-value | N = 351 | P-value | N = 223 | P-value | N = 995 | P-value | ||
| Age | 62 (60.8 ± 7.1) | 59 (58.0 ± 7.9) | <0.001 | 61 (60.1 ± 7.3) | 0.38 | 60 (59.5 ± 7.2) | 0.044 | 61 (60.4 ± 6.9) | 0.95 | 62 (60.0 ± 7.6) | 0.15 | |
| Male | 454 (72.2) | 823 (63.1) | - | 393 (66.4) | - | 236 (66.4) | - | 140 (62.8) | - | 634 (63.7) | - | |
| Anti-hypertensive agent and anti-dyslipidemia agent | None | 181 (28.8) | 486 (37.2) | - | 176 (29.7) | - | 93 (26.5) | - | 79 (35.4) | - | 310 (31.2) | - |
| Both of them | 174 (27.7) | 318 (24.4) | - | 212 (25.8) | - | 115 (32.8) | - | 51 (22.9) | 302 (30.4) | - | ||
| One of them | 274 (43.6) | 501 (38.4) | - | 204 (34.5) | - | 143 (40.7) | - | 93 (41.7) | - | 383 (38.5) | - | |
| HbA1c (NGSP %) | 7.4 (7.9 ± 1.7) | 7.2 (7.7 ± 1.6) | 0.004 | 6.7 (6.9 ± 1.2) | <0.001 | 6.7 (6.9 ± 1.2) | <0.001 | 7.0 (7.1 ± 1.3) | <0.001 | 7.4 (7.8 ± 1.5) | 0.90 | |
| Minimum | 4.7 | 5.0 | 4.9 | 5.1 | 4.6 | 5.1 | ||||||
| Maximum | 14.5 | 15.1 | 15.5 | 12.2 | 15 | 17.7 | ||||||
| <6.5 % | 100 (15.9) | 216 (16.6) | 224 (37.8) | 125 (35.6) | 60 (26.9) | 89 (8.9) | ||||||
| - | - | - | - | - | ||||||||
| 6.5% ≤ | 529 (84.1) | 1089 (83.5) | 369 (62.2) | 226 (64.4) | 163 (73.1) | 906 (91.1) | ||||||
| Duration of administration of baseline drug (days) | 537 (457 ± 282) | 612 (476 ± 278) | 0.45 | 486 (453 ± 273) | 1.00 | 521 (473 ± 249) | 0.86 | 575 (499 ± 246) | 0.16 | 281 (320 ± 241) | <0.001 | |
Data are n(%) or median (mean ± standard deviation). P-value: Dunnett’s test for SU